Emicizumab in the Treatment of Acquired Haemophilia: A Case Report

Moehnle, Patrick; Pekrul, Isabell; Spannagl, Michael; Sturm, Andreas; Singh, Delila und Dechant, Claudia (2019): Emicizumab in the Treatment of Acquired Haemophilia: A Case Report. In: Transfusion Medicine and Hemotherapy, Bd. 46, Nr. 2: S. 121-123

Abstract

The prognosis of acquired haemophilia A (AHA) is severe and treatment options are limited. Emicizumab is a novel bispecific humanized monoclonal antibody in the treatment of inherited AHA with inhibitors. An 83-year-old AHA patient with congestive heart failure and a high risk for thromboembolic and cardiac events who had initially been treated successfully with steroids and substitution of recombinant B-domain-deleted porcine FVIII developed severe bleeding complications and a secondary increase in inhibitor titres after 4 weeks of treatment. Conventional therapeutic strategies failed, and the patient was subsequently treated with emicizumab on off-label and named patient use premises. After the application of emicizumab, the clinical conditions stabilized and no further substitution of coagulation factors was needed. The patient could be discharged and survived 36 days in a cardiac rehabilitation centre without indications for spontaneous bleeding or thromboembolic events. We suggest that the effects of emicizumab in acquired haemophilia should be evaluated in clinical trials. (c) 2019 S. Karger AG, Basel

• Dokumententyp: Zeitschriftenartikel
• Fakultät: Medizin
• Themengebiete: 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit
• ISSN: 1660-3796
• Sprache: Englisch